Nordic Pharma joins the Pharmaceutical Supply Chain Initiative
We are pleased to announce that Nordic Pharma has joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member as of February 2023.
Driving sustainable change in our supply chain is a key pillar of our Corporate Social Responsibility (CSR) strategy, and this marks an important step into this direction. By joining PSCI, we will join industry experts in collectively working towards better business conditions, ultimately driving our common goal of greener supply chains. We commit to uphold the responsible business principles and continue to grow ethically, always with a long-term vision.
Small steps, big impact. Our Sustainability journey continues !
If you’d like to find out more about the PSCI, click here.
News related to this subject
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY AMRING PHARMACEUTICALS INC., ANNOUNCES JAI G. PAREKH, MD, MBA AS CHIEF COMMERCIAL OFFICER, EYE CARE U.S.
NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY AMRING PHARMACEUTICALS INC., ANNOUNCES JAI G. PAREKH, MD, MBA AS CHIEF COMMERCIAL OFFICER, EYE CARE U.S.
Nordic Pharma recently expanded its pharmaceutical expertise in the U.S. by acquiring Visant Medical, Inc. (Visant), a leader in medical technology innovation in Dry Eye Disease (DED). This included the FDA-cleared hyaluronic acid derivative LACRIFILL®, a canalicular occlusive device, which is intended to temporarily block tear drainage by the occlusion of the canalicular system.
“With this exciting acquisition and our global plans for LACRIFILL, Dr. Parekh’s 25 years of eye care experience, strategic leadership, and deep understanding of eye care and the industry, make him the perfect choice to guide our commercial entry into the U.S. market,” saidCharlotte Phelps, CEO, Nordic Pharma. “As a practicing ophthalmologist, Dr. Parekh’s patient-driven focuswill also be invaluable for making a sustainable impact on the health of people with dry eye disease.”
Philip Gioia, President of the U.S. team that will launch LACRIFILL under the Nordic Pharma brand said “I look forward to partnering with Jai in his new role. I’ve had the great opportunity to work with him while at other leading global Ophthalmology companies. He brings a world class, innovative, fresh perspective to eye care and his background, experience anarmamentariad reputation in our industry is second to none. In addition, having Andy Corley of Yelroc Consulting as a commercial advisor to Nordic Pharma following the Visant Medical acquisition, clearly sets us up for excellence as we prepare to launch LACRIFLL later this year.”
“I am honored to be a part of Nordic Pharma, a company known for its commitment to innovation and improving patient outcomes,” said Dr. Parekh. “I look forward to contributing to the growth and success of the organization by helping lead impactful commercial strategies. There are many ways to take care of dry eye patients and with this huge market opportunity, we believe LACRIFILL will be a significant part of the armamentaria.”
Nordic Pharma is a part of SEVER Life Sciences, a holding company created in 2019 that brings together three diverse but complementary companies that offer a wide range of products, pharmaceutical development services and delivery technologies.
future developments or otherwise.
Kate Popova
Contracts Administration Lead
Phone : 610-285-1699
ekaterina.popova@amringpharma.com
Draupnir Holdings Ltd have officially merged with Nordic Group B.V
Draupnir Holdings Ltd have officially merged with Nordic Group B.V
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. Announces Name Change to Nordic Pharma, Inc. Under New Nordic Group, B.V. Ownership
Amring Pharmaceuticals Inc. (“Amring”) announces its name change to Nordic Pharma, Inc. on March 4, 2024, following the change in ownership of the company from SEVER Life Sciences, B.V. to Nordic Group, B.V., a subsidiary of SEVER Life Sciences B.V., which occurred on June 1, 2023.
The change in the corporate name provides for better alignment strategically with the parent company headquartered in the Netherlands and its subsidiaries worldwide. Together, the companies look to expand the global footprint in Eye Care, Rheumatology, Woman’s Health, and Critical Care for branded products as well as strengthening their generic product business in the U.S.
As part of this growth strategy, Nordic Pharma recently acquired Visant Medical, Inc., a leader in medical technology innovation in Dry Eye Disease (DED). The acquisition included the FDA cleared hyaluronic acid derivative LACRIFILL® canalicular gel, which is intended to temporarily block tear drainage by the occlusion of the canalicular system. Nordic Pharma will be launching LACRIFILL in the U.S. in Q2 2024 followed by a global rollout.
Charlotte Phelps, CEO of Nordic Pharma said, “The strategic acquisition and merger of the US business unit is a cornerstone of Nordic Pharma's global expansion. With a range of ophthalmology products currently in phase II development, combining this with our existing assets and leveraging the expertise of our US leadership in ophthalmics is imperative for driving the success of these programs.”
“I'm excited to be leading Nordic Pharma U.S. at this dynamic stage of the company as we continue focusing on providing quality generics to our customers and their patients in the U.S. while building out an innovative proprietary ophthalmic business,” said Philip Gioia, President of Nordic Pharma U.S. “The timing could not be better as new ophthalmic innovations are becoming near-term ready for commercialization and I believe Nordic Pharma can capitalize and compete effectively as a newer specialty ophthalmic player in the U.S. and globally.”